Sign in

    Paul Rosenbaum • SWR

    Paul Rosenbaum is an equity analyst at SWR, specializing in financial sector research with a focus on European banking and insurance companies. Throughout his career, he has covered major firms such as Deutsche Bank, Allianz, and Commerzbank, earning a strong reputation for accurate stock calls and steady performance. Rosenbaum began his analyst career in the early 2010s, previously working at smaller regional firms before joining SWR in 2018. He holds FINRA Series 7 and Series 63 licenses and has been recognized by industry platforms for maintaining a call success rate above 62% and generating positive annualized returns for his coverage universe.

    Paul Rosenbaum's questions to Dyadic International Inc (DYAI) leadership

    Paul Rosenbaum's questions to Dyadic International Inc (DYAI) leadership • Q1 2025

    Question

    Paul Rosenbaum of SWR questioned the company's resource allocation, asking when Dyadic would shift its spending away from long-term, grant-funded research towards its more immediate non-pharmaceutical commercial opportunities.

    Answer

    COO Joe Hazelton responded that the strategic shift is happening "now." He explained that the company is reprioritizing resources to focus on commercial-ready products and that the human health platform development is largely complete, now relying on partners to advance it further. The focus is now on product development, not platform development.

    Ask Fintool Equity Research AI